메뉴 건너뛰기




Volumn 23, Issue 3, 2004, Pages 235-239

Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: Results of a double-blind clinical trial versus piperacillin-tazobactam

Author keywords

Complicated skin infections; Ertapenem; S. aureus

Indexed keywords

ERTAPENEM; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM;

EID: 1442287486     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.07.013     Document Type: Article
Times cited : (16)

References (15)
  • 1
    • 0035011978 scopus 로고    scopus 로고
    • In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers
    • Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:2001;1915-1918.
    • (2001) Antimicrob. Agents Chemother. , vol.45 , pp. 1915-1918
    • Fuchs, P.C.1    Barry, A.L.2    Brown, S.D.3
  • 3
    • 0036604093 scopus 로고    scopus 로고
    • Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: Results of a prospective, randomized, double-blind multicenter study
    • Graham D., Lucasti C., Malafaia O.et al. Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis. 34:2002;1460-1468.
    • (2002) Clin. Infect. Dis. , vol.34 , pp. 1460-1468
    • Graham, D.1    Lucasti, C.2    Malafaia, O.3
  • 4
    • 0037648561 scopus 로고    scopus 로고
    • Ertapenem once a day versus piperacillin-tazobactam every 6 h for treatment of acute pelvic infections: A prospective, multicenter, randomized double-blind study
    • Roy S., Higareda I., Angel-Muller E.et al. Ertapenem once a day versus piperacillin-tazobactam every 6 h for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study. Infect. Dis. Obstet. Gynecol. 11:2003;1-11.
    • (2003) Infect. Dis. Obstet. Gynecol. , vol.11 , pp. 1-11
    • Roy, S.1    Higareda, I.2    Angel-Muller, E.3
  • 5
    • 0037315316 scopus 로고    scopus 로고
    • Results of a double-blind, randomized comparative phase III trial of ertapenem vs. piperacillin/tazobactam for treatment of complicated intraabdominal infections
    • Solomkin J.S., Choe K.A., Rotstein O.D.et al. Results of a double-blind, randomized comparative phase III trial of ertapenem vs. piperacillin/tazobactam for treatment of complicated intraabdominal infections. Ann. Surg. 237:2003;235-245.
    • (2003) Ann. Surg. , vol.237 , pp. 235-245
    • Solomkin, J.S.1    Choe, K.A.2    Rotstein, O.D.3
  • 6
    • 0037090185 scopus 로고    scopus 로고
    • A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults
    • Ortiz-Ruiz G., Caballero-Lopez J., Friedland I., Woods G.L., Carides A. the Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin. Infect. Dis. 34:2002;1076-1083.
    • (2002) Clin. Infect. Dis. , vol.34 , pp. 1076-1083
    • Ortiz-Ruiz, G.1    Caballero-Lopez, J.2    Friedland, I.3    Woods, G.L.4    Carides, A.5
  • 7
    • 0036292299 scopus 로고    scopus 로고
    • A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults
    • Jimenez-Cruz F., Jasovich A., Cajigas J.et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Urology. 60:2002;16-22.
    • (2002) Urology , vol.60 , pp. 16-22
    • Jimenez-Cruz, F.1    Jasovich, A.2    Cajigas, J.3
  • 8
    • 0032802191 scopus 로고    scopus 로고
    • Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin
    • Nichols R.L., Graham D.R., Barriere S.L.et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin, or vancomycin. J. Antimicrob. Chemother. 44:1999;263-273.
    • (1999) J. Antimicrob. Chemother. , vol.44 , pp. 263-273
    • Nichols, R.L.1    Graham, D.R.2    Barriere, S.L.3
  • 9
    • 0032867146 scopus 로고    scopus 로고
    • Optimal treatment of complicated skin and skin structure infections
    • Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 4:1999;19-23.
    • (1999) J. Antimicrob. Chemother. , vol.4 , pp. 19-23
    • Nichols, R.L.1
  • 10
    • 0027326250 scopus 로고
    • Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate
    • Tan J.S., Wishnow R.M., Taklan D.A., Duncanson E.F., Norden C.W. the Piperacillin/Tazobactam Skin and Skin Structure Study Group Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. Antimicrob. Agents Chemother. 37:1993;1580-1586.
    • (1993) Antimicrob. Agents Chemother. , vol.37 , pp. 1580-1586
    • Tan, J.S.1    Wishnow, R.M.2    Taklan, D.A.3    Duncanson, E.F.4    Norden, C.W.5
  • 11
    • 0035145047 scopus 로고    scopus 로고
    • Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections
    • Siami G., Christou N., Eiseman I., Tack K.J. the clinafloxacin severe skin and soft tissue infections study group Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob. Agents. Chemother. 45:2001;525-531.
    • (2001) Antimicrob. Agents. Chemother. , vol.45 , pp. 525-531
    • Siami, G.1    Christou, N.2    Eiseman, I.3    Tack, K.J.4
  • 12
    • 0037102954 scopus 로고    scopus 로고
    • Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial
    • Graham D.R., Talan D.A., Nichols R.L.et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin. Infect. Dis. 35:2002;381-389.
    • (2002) Clin. Infect. Dis. , vol.35 , pp. 381-389
    • Graham, D.R.1    Talan, D.A.2    Nichols, R.L.3
  • 13
    • 0026492838 scopus 로고
    • General guidelines for the clinical evaluation of anti-infective drug products
    • Beam T.R. Jr., Gilbert D.N., Kunin C.M. General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. 15:1992;S5-32.
    • (1992) Clin. Infect. Dis. , vol.15 , pp. 5-32
    • Beam, T.R.Jr.1    Gilbert, D.N.2    Kunin, C.M.3
  • 14
    • 0003655628 scopus 로고    scopus 로고
    • NCCLS document M2-A6. Wayne, PA: National Committee for Clinical Laboratory Standards;
    • National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard. NCCLS document M2-A6. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
    • (1997) Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.